Clinical Trial
Study Details
Oral administration of IMR-687 once daily with or without HU.
Oral administration of placebo once daily with or without HU.
Study of IMR-687 in adult participants with sickle cell anemia (SCA) (homozygous HbSS or sickle-β0 thalassemia).
Study Overview
This is a proof-of-concept study in adult SCA participants, ages 18 to 55 years old, to examine the safety, tolerability, and pharmacokinetic (PK), as well as the potential pharmacodynamic (PD) effects and clinical efficacy, of IMR-687 across a range of doses.
IMR-687 was administered in 2 populations of participants with SCA: those who were not receiving hydroxyurea (HU) and those who were receiving a stable dose of HU according to standard of care.
Contacts and Locations
UCSF Benioff Children's Hospital Oakland
Oakland, California 94609
United States
University of Connecticut Health Center
Farmington, Connecticut 06030
United States
Foundation for Sickle Cell Disease Research
Hollywood, Florida 33021
United States
University of Illinois
Chicago, Illinois 60612
United States
Loretto Hospital
Chicago, Illinois 60644
United States
Medical University of South Carolina
Charleston, South Carolina 29425
United States
Baylor Scott & White Health
Temple, Texas 76508
United States
Sandwell & West Birmingham Hospital
Birmingham
B18 7QH
United Kingdom
Bristol Haematology and Oncology Centre
Bristol
BS2 8ED
United Kingdom
Royal London Hospital
London
E1 1BB
United Kingdom
University College London Hospital
London
NW1 2PG
United Kingdom
Guy's Hospital
London
SE1 9RT
United Kingdom
Oxford Cancer & Haematology Centre, The Churchill Hospital
Oxford
OX3 7LE
United Kingdom